1246200-39-4
Chemical Structure
Ulodesine succinate
Synonym(s): BCX4208 succinate
- CAS No.: 1246200-39-4
- Formula:C12H16N4O3·1/2C4H6O4
- Molecular Weight:323.33
SMILES: OC(CCC(O)=O)=O.O=C(N=CN1)C2=C1C(CN3C[C@@H]([C@H](C3)O)CO)=CN2.[1/2]
Biological Activity: Ulodesine succinate (BCX4208 succinate) is a purine nucleoside phosphorylase (PNP) inhibitor, with an IC50 of 2.293 nM against human PNP, and low nanomolar IC50 values against mouse, rat and monkey PNP. Ulodesine succinate blocks the production of uric acid precursors, reduces serum uric acid levels, clears accumulated uric acid in the blood, and elevates the levels of purine nucleosides including guanosine. Ulodesine succinate reduces the counts of total lymphocytes, T lymphocytes and lymphocyte subsets, inhibits the proliferation of cancer cells and activated lymphocytes, and enhances vaccine immune responses. Ulodesine succinate can be used in research related to hyperuricemia and gout[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ulodesine succinate | Ulodesine succinate (BCX4208 succinate) is a purine nucleoside phosphorylase (PNP) inhibitor, with an IC50 of 2.293 nM against human PNP, and low nanomolar IC50 values against mouse, rat and monkey PNP. Ulodesine succinate blocks the production of uric acid precursors, reduces serum uric acid levels, clears accumulated uric acid in the blood, and elevates the levels of purine nucleosides including guanosine. Ulodesine succinate reduces the counts of total lymphocytes, T lymphocytes and lymphocyte subsets, inhibits the proliferation of cancer cells and activated lymphocytes, and enhances vaccine immune responses. Ulodesine succinate can be used in research related to hyperuricemia and gout. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. van der Meer JW, et al. Abstract!. The Netherlands journal of medicine. 2002 Dec;60(11):418. [Content Brief]
- [2]. Shahid H, et al. Investigational drugs for hyperuricemia. Expert opinion on investigational drugs. 2015;24(8):1013-30. [Content Brief]
- [3]. Bantia S. Purine Nucleoside Phosphorylase Inhibitors as Novel Immuno-Oncology Agent and Vaccine Adjuvant. Int J Immunol Immunother. 2020;7:043.
- [4]. Tang DH, et al. Inosine induces acute hyperuricaemia in rhesus monkey (Macaca mulatta) as a potential disease animal model. Pharm Biol. 2021 Dec;59(1):175-182. [Content Brief]
- [5]. Evans GB, et al. Immucillins in Infectious Diseases. ACS infectious diseases. 2018 Feb 09;4(2):107-117. [Content Brief]
Keywords
